- In December 2024, Yale, part of the ASSA ABLOY Group, launched the Linus Stress Management Drug L2, the next generation of its flagship Linus product. This new Stress Management Drug offers improved performance, enhanced security features, and seamless integration with popular smart home ecosystems. The Linus Stress Management Drug L2 is designed to provide users with keyless entry, remote access control, and activity monitoring through a mobile application. By introducing this advanced product, Yale aims to meet the growing demand for secure and convenient access solutions in residential settings.
- In March 2025, Allegion plc, a global provider of security products and solutions, announced the acquisition of ELATEC, a company specializing in advanced access control technology. This strategic acquisition aims to enhance Allegion's product offerings by integrating ELATEC's innovative solutions, particularly in the areas of mobile and cloud-based access control. The merger is expected to accelerate the adoption of smart, secure, and scalable access solutions globally, positioning Allegion as a leader in the rapidly evolving access control market.
- In April 2025, Cingulate Inc., a biopharmaceutical company based in Kansas City, announced the development of CTx-2103, a once-daily formulation of buspirone for the treatment of anxiety disorders. This new formulation aims to improve patient adherence and reduce the use of benzodiazepines, which are associated with withdrawal and dependency issues
